Understanding how acute myeloid leukemia avoids the immune system
Pathways of Immune Evasion in Acute Myeloid Leukemia
This study is looking at how acute myeloid leukemia (AML) hides from the immune system, especially T cells, and aims to find ways to boost these T cells to help fight the cancer better, which could lead to better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11032008 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which acute myeloid leukemia (AML) evades detection and attack by the immune system, particularly focusing on T cells. The study aims to explore how the presence of T cells in the bone marrow correlates with patient survival and how immune checkpoint blockade can potentially reverse T cell suppression in AML. By examining the epigenetic changes and signaling pathways involved in T cell exhaustion, the research seeks to identify new therapeutic strategies that could enhance immune responses against AML. Patients may benefit from insights that could lead to improved immune therapies for this aggressive form of leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who are seeking new treatment options.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with any form of blood cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immune therapies for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in using immune checkpoint blockade to enhance T cell function in AML, indicating that this approach has potential for success.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Lind, Evan Ferguson — Oregon Health & Science University
- Study coordinator: Lind, Evan Ferguson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.